Navigation Links
Glaucoma surgery in the blink of an eye
Date:9/22/2007

TEL AVIV Prof. Ehud Assia, of Tel Aviv Universitys Sackler School of Medicine is, quite simply, a rock star in the field of eye surgery.

One of a small number of surgeons in the world who currently perform a complicated form of glaucoma surgery, Prof. Assia has developed a novel laser device that promises to revolutionize treatment of the disease. The laser, called the OTS134 for now, is expected to give most practicing eye surgeons the ability to master complex glaucoma surgery very quickly.

Glaucoma, nicknamed the silent sight thief, is the second leading cause of blindness in the West. Glaucoma is a serious problem that starts to cause nerve damage to people without them realizing that anything is happening to their eyesight, often before it is too late, says Prof. Assia, who is also the director of Ophthalmology at Meir Hospital in Israel, which treats thousands of glaucoma patients each year.

The most common surgical treatment in use today perforates the wall of the eye, often resulting in collapse of the eyeball, infection, cataract formation and other complications. A more effective and elegant approach, a specialty of Prof. Assia's, involves penetration of the eye wall to a depth of only about 95 percent, leaving a razor-thin layer intact. The difference between success and failure may amount to just a few microns.

This highly-specialized non-penetrating surgery, requiring years of rigorous training and great skill, is performed by only a small number of surgeons at leading international ophthalmology centers. But a small observation led Prof. Assia to think about a method that could make the procedure accessible to eye surgeons without the long and involved training.

Several years ago I served as a consultant for a company that produces CO2 lasers, which are used for different kinds of cosmetic and skin surgery. Because it is a relatively strong type of laser, it was not a likely candidate for use on something as delicate as the eye. However, one of the CO2 laser's unique characteristics is that it does not function when it comes in contact with liquid. It occurred to me that this would be a perfect fit for non-penetrating surgery, because the moment the CO2 laser came in contact with the intra-ocular liquid, it would automatically shut off, he recalls.

Working in partnership with the Israeli-based company IOPtima, Prof. Assia has already carried out a series of successful human trials. A larger worldwide study will take place this year before the company launches the OTS134 as it plans to do in the United States by the middle of 2008.

Glaucoma affects 3 million Americans every year, with onset around the age of 40. It is a disease that is brought on by a seemingly harmless increase of pressure in the eyeball. When this pressure builds up over time, the aging body cannot seem to correct the pressure effectively. Glaucoma eventually damages the optical nerve in the eye, with extreme tunnel vision and complete blindness ensuing.

There are drug treatments that can reduce the intra-ocular pressure, but that means life-long treatment involving two or three kinds of eye drops three times a day," says Prof. Assia. "We find that a large number of patients dont comply with this treatment, especially because the harmful effects of not taking the medicine properly are not immediately felt.

Although he counsels that surgical approaches to glaucoma also carry risks, the OTS134 is a promising tool for more widespread treatment with fewer complications.


'/>"/>

Contact: Barbara Schreibman
bschreibman@aftau.org
212-742-9080
American Friends of Tel Aviv University
Source:Eurekalert

Related medicine news :

1. Glaucoma may be delayed by eye drops
2. Glaucoma & Ocular Hypertension more likely in patients with refractive errors
3. Progression of Glaucoma could be controlled with early detection
4. Tight necktie may raise glaucoma risk
5. Early Screening Required for Glaucoma
6. Adding An Additional Drug May Help Patients With Glaucoma
7. Heavy Computer Use May Result In Glaucoma
8. A Drop a day Can Keep Glaucoma At Bay
9. Millions Of Diabetic And Glaucoma Patients Risk Blindness
10. Glaucoma Could Cause Vision Loss In 60 Million People By 2010
11. Glaucoma Camp Held
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... spark a conversation on the current obstacles facing infection prevention and offer strategies ... deaths caused by these infections. , The print component of “Fighting Infection” ...
(Date:3/24/2017)... Dallas, Texas (PRWEB) , ... March 24, 2017 , ... ... Budget Office score is invalid because it does not obey the rules Congress has ... million full-time equivalent jobs, which the GOP reform would restore. Yet, it estimates a ...
(Date:3/24/2017)... Sedona, Arizona (PRWEB) , ... March 24, 2017 ... ... Shamangelic Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Jorge Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She ... Record, The majority of cases litigated under ERISA involve claims for long-term disability ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located in Southlake, ... leads programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” ... designed to teach how to maximize their sales efforts, as well as how ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... PUNE, India , March 24, 2017 ... conjugates market has been growing rapidly as the global sales of ... Globally, the growth in the antibody drug conjugates market is driven ... incidences of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and ...
(Date:3/24/2017)... 2017  GenomeDx Biosciences today announced that six abstracts ... Prostate Cancer Classifier tests will be presented at the ... Congress held March 24 to 28, 2017 in ... is Europe,s largest urological event ... urological field. The abstract titled "Muscle invasive ...
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
Breaking Medicine Technology: